NCT07342283
Not yet recruiting
Phase 2
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Affiliated Hospital of Nantong University0 sites30 target enrollmentStarted: December 25, 2025Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 30
- Primary Endpoint
- Pathologic complete response (pCR) rates
Overview
Brief Summary
This is a single-center, single-arm, prospective study enrolling 30 patients with stage II-III triple-negative breast cancer. The neoadjuvant regimen consists of QL1706 combined with carboplatin plus albumin-bound paclitaxel (21-day cycles for 4 cycles) followed by QL1706 combined with doxorubicin/epirubicin plus cyclophosphamide (21-day cycles for 4 cycles). The treatment observation period is 1 year, and the primary endpoint is the pathological complete response rate.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically confirmed newly diagnosed ER-/HER2- breast cancer. ER and PR with Allred score \<3 or \<1% positively stained cells in tumor infiltrating components. HER2 negativity defined as 0 or 1+ by FISH or IHC staining per NCCN guidelines;
- •Clinical stage II or III breast cancer eligible for neoadjuvant chemotherapy (per AJCC 8th edition: at least T2 any N M0, or any T if N+), with treatment goal of complete surgical resection following neoadjuvant therapy;
- •Tumor size ≥2 cm by clinical or imaging assessment per WHO criteria. Patients with histologically confirmed or clinically palpable lymph nodes are eligible regardless of tumor size;
- •Treatment-naïve subjects;
- •Age ≥18 years, both genders eligible;
- •ECOG performance status 0-1;
- •Adequate bone marrow, cardiac, and organ function;
- •Women of childbearing potential must have a negative pregnancy test (serum or urine HCG) within 30 days prior to study enrollment and must practice effective contraception during the study;
- •Ability to comprehend and provide written informed consent.
Exclusion Criteria
- •History of invasive malignancies within 5 years prior to signing the informed consent form, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or carcinoma in situ of the cervix;
- •Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months;
- •Stage IV metastatic breast cancer;
- •Administration of a vaccine within 30 days before the first dose of the study treatment;
- •Subjects with severe systemic diseases;
- •Subjects with active infections (including but not limited to HIV, hepatitis B or C, tuberculosis);
- •Severe cardiovascular diseases, such as: history of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass grafting within the past 6 months; or congestive heart failure (CHF) of New York Heart Association (NYHA) class II-IV, or history of CHF NYHA class III or IV;
- •Lactating women should discontinue breastfeeding during the study;
- •Subjects with known allergies to the study drug or any of its excipients;
- •Any other condition deemed inappropriate for participation in the study by the investigator.
Outcomes
Primary Outcomes
Pathologic complete response (pCR) rates
Time Frame: Up to approximately 9 months
pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.
Secondary Outcomes
- Objective response rate（ORR）(Up to approximately 27-30 weeks)
- 3y-EFS(Up to approximately 3 years)
- Overall survival (OS)(Up to approximately 8 years)
- Adverse events(up to 18 months)
Investigators
Similar Trials
Suspended
Phase 2
The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a non-randomized, open-label, single-arm phase II study2022-501322-38-00Institut fuer Klinische Krebsforschung IKF GmbH46
Not yet recruiting
Phase 2
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)NCT07283692RenJi Hospital46
Not yet recruiting
Phase 3
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007)2024-514500-14-00Merck Sharp & Dohme LLC206
Recruiting
Phase 1
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerNCT07322094TORL Biotherapeutics, LLC60
Active, not recruiting
Phase 3
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body2023-507522-16-00Arcus Biosciences Inc.152